ロード中...
Efficacy and safety of osimertinib in treating EGFR‐mutated advanced NSCLC: A meta‐analysis
Osimertinib is the only Food and Drug Administration‐approved third‐generation epidermal growth factor receptor (EGFR) tyrosine‐kinase inhibitor (TKI). A meta‐analysis was performed to aggregate the mixed results of published clinical trials to assess the efficacy and safety of osimertinib. A system...
保存先:
| 出版年: | Int J Cancer |
|---|---|
| 主要な著者: | , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
John Wiley & Sons, Inc.
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6590181/ https://ncbi.nlm.nih.gov/pubmed/30613959 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.32097 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|